88
edits
Changes
Jump to navigation
Jump to search
mLine 7:
Line 7: − [[Merck]] has developed a [[vaccine]] against the four most prevalent sexually transmitted strains of HPV; see [[Gardasil]]. [[GlaxoSmithKline]] later released its own vaccine, Cervarix, which protects against the two most prevalent high risk strains. Both vaccines are manufactured using recombinant viral capsid proteins. +
no edit summary
HPV is the most prevalent sexually transmitted disease. Population studies testing for the presence of antibodies against viral proteins suggest that around 75% of American women will be infected with at least one sexually transmitted strain of the virus at some point in their lives. These numbers are surprisingly consistent across all demographics examined.
HPV is the most prevalent sexually transmitted disease. Population studies testing for the presence of antibodies against viral proteins suggest that around 75% of American women will be infected with at least one sexually transmitted strain of the virus at some point in their lives. These numbers are surprisingly consistent across all demographics examined.
==HPV Vaccine==
==HPV Vaccine==
[[Merck]] has developed a [[vaccine]] against the four most prevalent sexually transmitted strains of HPV; see [[Gardasil]]. [[GlaxoSmithKline]] later released its own vaccine, Cervarix, which protects against the two most prevalent high risk strains. Both vaccines are manufactured using recombinant viral capsid proteins.
A new study looking at the prevalence of human papillomavirus (HPV) infections in girls and women before and after the introduction of the HPV vaccine shows a significant reduction in vaccine-type HPV in U.S. teens. The study, published in [the June issue of] The Journal of Infectious Diseases reveals that since the vaccine was introduced in 2006, vaccine-type HPV prevalence decreased 56 percent among female teenagers 14-19 years of age. <ref>http://www.cdc.gov/media/releases/2013/p0619-hpv-vaccinations.html</ref>
A new study looking at the prevalence of human papillomavirus (HPV) infections in girls and women before and after the introduction of the HPV vaccine shows a significant reduction in vaccine-type HPV in U.S. teens. The study, published in [the June issue of] The Journal of Infectious Diseases reveals that since the vaccine was introduced in 2006, vaccine-type HPV prevalence decreased 56 percent among female teenagers 14-19 years of age. <ref>http://www.cdc.gov/media/releases/2013/p0619-hpv-vaccinations.html</ref>